下载此文档

FMEA辉瑞企业培训资料.pptx


文档分类:办公文档 | 页数:约36页 举报非法文档有奖
1/36
下载提示
  • 1.该资料是网友上传的,本站提供全文预览,预览什么样,下载就什么样。
  • 2.下载该文档所得收入归上传者、原创者。
  • 3.下载的文档,不会出现我们的网址水印。
1/36 下载此文档
文档列表 文档介绍
Managing Pharmaceutical Quality: Risk or Uncertainty Management?
Ajaz S. Hussain, .
Office of Pharmaceutical Sciencet Standards”
Science of Design + Manufacturing Science = Quality by Design
Risk/Benefit and Quality
Harm
Acceptable
Risk/Benefit
Quality
Label
No benefit (placebo effect)
Managing Pharmaceutical Quality
Quality of a new molecular entity (a potential drug)
Intrinsic pharmacological & toxicological attributes
Identity
Complexity
A range of uncertainty with respect to identity of “active moiety”, purity and stability of materials used in evaluation of pharmacological and toxicological attributes (if a mixture; variability adds additional uncertainty)
Variability in the extent and rate of delivery of “active moiety” to the sites of action and variability in the pharmacological & toxicological response and measurement systems further adds uncertainty
Managing Pharmaceutical Quality
Quality of a drug product
For establishing proposed therapeutic claim (label)
Drug product manufactured for clinical trials
After successful demonstration of therapeutic claim (acceptable risk-to-benefit ratio)
Drug product manufactured for commercial distribution
Life cycle of the product (shelf-life, exclusivity period, generic competition, post-approval changes,…)
Drug product manufactured at many different facilities, changes in the process, different manufactures,…
Uncertainty, Variability and Risk
Quality – Clinical Connection
How does a product formulation and its manufacturing process impact clinical performance?
Without a clear understanding we are uncertain (lack of knowledge)
In decision making there are many advantages in distinguishing between uncertainty, variability (random variation) and risk
Goals and Characteristics of a Quality Decision System: Example
Goal: expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling
Characteristics
Uncertai

FMEA辉瑞企业培训资料 来自淘豆网m.daumloan.com转载请标明出处.

相关文档 更多>>
非法内容举报中心
文档信息
  • 页数36
  • 收藏数0 收藏
  • 顶次数0
  • 上传人wz_198613
  • 文件大小918 KB
  • 时间2022-07-09
最近更新